Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Factors linked to significant fibrosis in NAFLD patients without NASH

29 Oct 2019

Patients with nonalcoholic fatty liver disease (NAFLD) may develop significant fibrosis in the absence of nonalcoholic steatohepatitis (NASH), with risk factors including fasting hyperglycaemia, severe steatosis, mild inflammation and the PNPLA3 I148M variant, according to a recent study.

Researchers looked at 1,738 patients (44.9 percent with severe obesity) in a cross-sectional liver biopsy cohort. Biopsy specimens had been analysed for the presence of NASH (steatosis [≥5 percent of hepatocytes], hepatocellular ballooning and lobular inflammation).

In the cohort, 571 patients (32.9 percent) had NASH and 389 had significant fibrosis (22.4 percent). Significant fibrosis was more prevalent in patients with vs without NASH (45.0 percent vs 11.3 percent). However, of the patients with significant fibrosis, as many as 132 (33.9 percent) had no NASH and 39 (10 percent) had no lobular inflammation.

The dissociation between NASH and fibrosis was stronger in patients with severe obesity (p<0.005). Steatosis, ballooning and lobular inflammation all showed an independent association with significant fibrosis (p<0.001), while age, adiposity, fasting hyperglycaemia and the PNPLA3 I148M variant were associated with fibrosis.

In the subgroup of patients without NASH, risk factors for significant fibrosis included steatosis grade and the PNPLA3 I148M variant. Factors associated with fibrosis were age, fasting hyperglycaemia, ballooning and inflammation.

In the validation cohort of 118 consecutive patients with NAFLD who underwent sequential liver biopsies, NASH was not present in 16 of 47 patients (34.0 percent) with clinically significant fibrosis. Among those with fibrosis but without NASH, fasting hyperglycaemia and more severe steatosis were associated with worsening of fibrosis (based on later biopsies; p=0.016).

The present data point to the presence of significant fibrosis in higher than expected proportion of patients with NAFLD, possibly owing to fluctuating disease activity and/or the underlying mechanisms of disease progression that may be partially different in different subgroups, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.